title: Characterization of a novel radiation-induced sarcoma cell line.
abstract: BACKGROUND
  Radiation-induced sarcoma (RIS) is a potential complication of cancer treatment. No widely available cell line models exist to facilitate studies of RIS.
  
  
  METHODS
  We derived a spontaneously immortalized primary human cell line, UACC-SARC1, from a RIS.
  
  
  RESULTS
  Short tandem repeat (STR) profiling of UACC-SARC1 was virtually identical to its parental tumor. Immunohistochemistry (IHC) analysis of the tumor and immunocytochemistry (ICC) analysis of UACC-SARC1 revealed shared expression of vimentin, osteonectin, CD68, Ki67 and PTEN but tumor-restricted expression of the histiocyte markers α1-antitrypsin and α1-antichymotrypsin. Karyotyping of the tumor demonstrated aneuploidy. Comparative genomic hybridization (CGH) provided direct genetic comparison between the tumor and UACC-SARC1. Sequencing of 740 mutation hotspots revealed no mutations in UACC-SARC1 nor in the tumor. NOD/SCID gamma mouse xenografts demonstrated tumor formation and metastasis. Clonogenicity assays demonstrated that 90% of single cells produced viable colonies. NOD/SCID gamma mice produced useful patient-derived xenografts for orthotopic or metastatic models.
  
  
  CONCLUSIONS
  Our novel RIS strain constitutes a useful tool for pre-clinical studies of this rare, aggressive disease. UACC-SARC1 is an aneuploid cell line with complex genomics lacking common oncogenes or tumor suppressor genes as drivers of its biology. The UACC-SARC1 cell line will enable further studies of the drivers of RIS.
authors: Department of Surgery and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
authors: Julie
authors: J
authors: Lang
authors: Weizhu
authors: W
authors: Zhu
authors: Brandon
authors: B
authors: Nokes
authors: Grishma
authors: G
authors: Sheth
authors: Petr
authors: P
authors: Novak
authors: Laura
authors: L
authors: Fuchs
authors: George
authors: G
authors: Watts
authors: Bernard
authors: B
authors: Futscher
authors: Neal
authors: N
authors: Mineyev
authors: Alexander
authors: A
authors: Ring
authors: Lauren
authors: L
authors: LeBeau
authors: Ray
authors: R
authors: Nagle
authors: Lee
authors: L
authors: Cranmer
mesh_terms: D000782:Aneuploidy; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor / Q000378:metabolism / Q000473:pathology*; D055028:Comparative Genomic Hybridization; D003593:Cytoplasm / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007621:Karyotyping; D019394:Ki-67 Antigen / Q000378:metabolism; D016513:Mice, SCID; D018895:Microsatellite Repeats; D008875:Middle Aged; D009374:Neoplasms, Experimental; D009381:Neoplasms, Radiation-Induced / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D015676:Osteonectin / Q000378:metabolism; D051059:PTEN Phosphohydrolase / Q000378:metabolism; D012509:Sarcoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D017422:Sequence Analysis, DNA; D014746:Vimentin / Q000378:metabolism; D000514:alpha 1-Antichymotrypsin / Q000378:metabolism; D000515:alpha 1-Antitrypsin / Q000378:metabolism; D000097382:CD68 Molecule
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D019394:Ki-67 Antigen; D015676:Osteonectin; D051059:PTEN Phosphohydrolase; D014746:Vimentin; D000514:alpha 1-Antichymotrypsin; D000515:alpha 1-Antitrypsin; C067980:CD68 antigen, human; D000097382:CD68 Molecule; C494929:PTEN protein, human
keywords: malignant fibrous histiocytoma; radiation-induced; sarcoma
references: Br J Cancer. 1997;75(1):94-100
references: 9000604
references: Breast Cancer Res Treat. 1998 Jan;47(2):101-9
references: 9497098
references: Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):18115-20
references: 20921380
references: Ann Surg. 2004 Jun;239(6):903-9; discussion 909-10
references: 15166970
references: Genes Dev. 2003 May 15;17(10):1253-70
references: 12756227
references: PLoS One. 2013 Jun 27;8(6):e67278
references: 23826254
references: Am J Pathol. 2010 Oct;177(4):2080-90
references: 20884963
references: Oncologist. 2012;17(3):405-18
references: 22334455
references: Cancer Lett. 2004 Feb 10;204(1):105-13
references: 14744540
references: Cancer Res. 2012 Feb 15;72(4):1013-22
references: 22232736
references: Cancer. 2012 May 15;118(10):2682-92
references: 21989796
references: Genome Biol. 2004;5(10):R80
references: 15461798
references: J Pathol. 1992 Sep;168(1):29-33
references: 1333524
references: Science. 2012 Jul 6;337(6090):104-9
references: 22628553
references: Ann Diagn Pathol. 2011 Dec;15(6):407-13
references: 21983422
references: Sarcoma. 2008;2008:459386
references: 18497869
references: Lab Invest. 1992 Oct;67(4):498-505
references: 1331610
references: Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8012-7
references: 11416159
references: Acta Oncol. 2008;47(8):1475-82
references: 18607853
references: Biostatistics. 2004 Oct;5(4):557-72
references: 15475419
references: Cancer Genet Cytogenet. 1990 Nov 1;50(1):125-37
references: 2253180
references: Cancer. 1996 May 1;77(9):1815-22
references: 8646679
references: J Exp Clin Cancer Res. 2010;29:153
references: 21092322
references: Mol Cancer Ther. 2009 Apr;8(4):713-24
references: 19372543
references: J Clin Oncol. 2010 Apr 20;28(12):2064-9
references: 20308666
references: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
references: 12629218
references: Hum Cell. 2009 Nov;22(4):85-93
references: 19874397
references: J Pathol. 2011 Jan;223(1):64-71
references: 21125665
references: J Clin Oncol. 2002 Nov 1;20(21):4344-52
references: 12409334
references: Br J Cancer. 1988 Sep;58(3):322-5
references: 3179184
references: Clin Cancer Res. 2001 Sep;7(9):2908-11
references: 11555609